Renal Disease and PKPD - PowerPoint PPT Presentation

1 / 89
About This Presentation
Title:

Renal Disease and PKPD

Description:

Kidney is the major organ of drug elimination from the human body ... TDF. Blood. Lumen. OAT1. MRP. Proximal. Tubule. Toxicology ... – PowerPoint PPT presentation

Number of Views:60
Avg rating:3.0/5.0
Slides: 90
Provided by: 14914
Category:
Tags: pkpd | disease | oat1 | renal

less

Transcript and Presenter's Notes

Title: Renal Disease and PKPD


1
Renal Disease and PK/PD
  • Anjay Rastogi MD PhD

2
Drugs and Kidneys
  • Kidney is the major organ of drug elimination
    from the human body
  • Renal disease and dialysis alters the
    pharmacokinetics and pharmacodynamics of most
    commonly used drugs
  • Polypharmacy is common in renal disease patients
    with a median of 8 drugs being used
  • Patients with renal disease on an average suffer
    from adverse effects as compared to the general
    population

3
  • Estimation of renal function
  • Effect of renal disease on PK and PD
  • Drug Nephrotoxicity
  • Management of poisoning

4
Nephron
Reabsorption
Filtration
  • Kidney regulates
  • Water
  • Acid-base balance
  • Electrolytes
  • Nitrogenous waste
  • excretion

Secretion
5
GFR as an Indicator of Kidney Function
  • GFR is an important indicator of CKD
  • Reduced GFR in patients with renal disease
    results from irreversible loss of nephrons1,2
  • Greater burden is placed on remaining nephrons
  • Hyperfiltration predisposes to further nephron
    destruction
  • 50 of nephrons can be lost without functional
    impairment1
  • Patients may still be asymptomatic, but are
    progressing toward end-stage chronic renal
    failure1

5
1. Ix JH et al. Lange Pathophysiology. Lange
Medical Books/McGraw Hill, Medical Publishing
Division 2006456-481 2. Eaton DC et al.
Vander's Renal Physiology. Lange Medical
Books/McGraw Hill, Medical Publishing Division
200424-36.
6
Defining GFR
  • Glomerular filtration
  • Process by which water and solutes in the blood
    pass from the vascular system through a
    filtration barrier into Bowman space
  • This filtrate is similar to blood plasma, with
    large plasma proteins excluded
  • GFR
  • Volume of filtrate formed per unit of time
  • Normal young adult male 180 L/d (125 mL/min/1.73
    m2)
  • Entire plasma volume is filtered by kidneys 60
    times per day

6
Eaton DC et al. Vanders Renal Physiology. Lange
Medical Books/McGraw Hill, Medical Publishing
Division 20041-23.
7
Factors Affecting GFR
  • Direct determinants of GFR
  • Permeability of capillaries and surface area
    (filtration coefficient)
  • Net filtration pressure (hydrostatic pressure in
    capillaries and in Bowman capsule, and glomerular
    capillary osmotic pressure resulting from
    proteins)
  • Other factors that affect GFR
  • Changes in renal arterial pressure, renal
    arteriolar resistance (dilation or constriction),
    and renal plasma flow
  • ? Intratubular pressureobstruction of tubule or
    urinary system
  • ? Osmotic pressureincreased protein
    concentration

7
Eaton DC et al. Vanders Renal Physiology. Lange
Medical Books/McGraw Hill, Medical Publishing
Division 200424-36.
8
Estimation of GFR
  • Inulin clearance
  • Iothalamate scans
  • 24 hour urine collection
  • eGFR
  • Creatinine

9
GFR versus Serum Creatinine
GFR versus Serum Creatinine
9.0
8.0
7.0
6.0
5.0
Serum Creatinine (mg/dL)
4.0
3.0
2.0
1.0
0.0
0
20
40
60
80
100
120
140
160
180
Inulin Clearance (mL/min/1.73 m2)
Available at http//medical.dictionary.thefreedict
ionary.com/. Accessed on March 1, 2005. Johnson
R, et al. Comprehensive Clinical Nephrology.
2000. Mosby. St. Louis. 4.15.14.15.15.
10
GFR Equations Compared
Cockcroft-Gault
MDRD
(0.742 if female)
(1.212 if black)
140 - age x weight (kg) 72 x PCr
x
x (0.85 symbol for female)
186.3 x PCr 1.154 x age 0.203 x
6 variable Cr, BUN, age, alb, race, sex 4
variable Cr, age, race, sex
Levey AS, et al. Ann Intern Med.
1999130(6)461-470. Abstract
11
Pharmacokinetics
12
Pharmacokinetics
  • Absorption and bioavailability
  • Drug distribution
  • Volume of distribution
  • Protein binding
  • Biotransformation and drug metabolism
  • Elimination

13
(No Transcript)
14
Bioavailability
  • Proportion of oral drug reaching systemic
    circulation
  • Affected by
  • Intestinal and drug permeability
  • First pass effect
  • Gut motility
  • pH

15
(No Transcript)
16
(No Transcript)
17
Plasma Protein Binding
  • Acidic drugs bind to albumin and basic drugs to
    a1-acid glycoprotein in the plasma
  • There is a decrease in binding of acidic drugs in
    CKD which has been attributed to changes in the
    binding site, accumulation of endogenous
    inhibitors of binding and decreased
    concentrations of albumin.
  • On the other hand the concentration of a1-acid
    glycoprotein does not change that much and
    actually might be increased in patients on HD and
    transplanted patients

18
(No Transcript)
19
Nephrotic Syndrome
  • Complex interaction
  • Hypoalbuminemia may result in lesser protein
    binding with more free drug in the plasma while
    at the same time there might be loss of albumin
    bound drug in the urine
  • Some drugs are also known to produce adverse
    effects more readily in patients with nephrotic
    syndrome eg clofibrate can produce severe muscle
    necrosis

20
Volume of Distribution (VD)
  • Apparent number as it does not correlate with any
    defined anatomic space
  • It is a ratio of the administered dose to plasma
    concentration at equilibrium
  • Concept important for predicting the loading dose

21
Factors affecting VD
  • Protein and tissue binding
  • Volume status

22
Metabolism
  • Drug metabolism occurs in the kidneys but to a
    lesser extent than the liver
  • Progressive CKD effects most body biochemical
    reactions including drug biotransformation
  • Reduction and hydrolysis reactions are slowed but
    glucuronidation, sulfation, conjugation and
    microsomal oxidation reactions occur at normal
    rates
  • Also important to keep in mind is the fact that
    even though the drug might not be eliminated by
    the kidney, their active metabolite might eg
    meperidine, nitrofurantoin and morphine

23
Dosing in a patient with renal insufficiency
24
(No Transcript)
25
(No Transcript)
26
(No Transcript)
27
Extracorporeal Drug Losses
28
Dialysis
  • Dialysis is extracorporeal purification of blood
  • Artificial Kidney

29
Dialysis
  • Diffusion of small molecules down their
    concentration gradient across a semipermeable
    membrane

30
(No Transcript)
31
(No Transcript)
32
RRT
  • Solute clearance
  • Diffusion
  • Convection
  • Fluid clearance

33
Hemo-Dialysis (HD)
  • Concentration difference across a semi-permeable
    membrane favors diffusive transport of small
    solutes (lt300 Da)

34
Diffusion
  • Urea is used as the marker for small molecule
    diffusion during dialysis
  • Diffusive clearance is a function of
  • Blood flow rate
  • Membrane surface area
  • Time

35
Hemo-Filtration (HF)
  • HF refers to the use of a transmembrane
    hydrostatic pressure (TMP) gradient to induce
    filtration of plasma water across the membrane
    which results in the convective transport of
    small and medium sized solutes by solvent drag
    (lt5-10 kDa)
  • Plasma concentration of the solute does not
    change
  • Replacement Fluid

36
Ultra-filtration
  • Removal of water during dialysis from the
    patients circulation
  • HD Transmembrane pressure gradient
  • PD Osmotically driven by glucose

37
Ultrafiltration
  • UF is a function of three factors
  • Transmembrane hydrostatic pressure
  • Ultra-filtration coefficient of dialysis membrane
  • Duration

38
Factors Affecting Drug Clearance by Dialysis
  • Drug
  • Molecular weight
  • Protein binding
  • Volume of distribution

39
Factors Affecting Drug Clearance by Dialysis
  • Dialysis
  • Composition of the dialyzer membrane
  • Surface area
  • Blood and dialysate flow
  • Mode IHD, PD or CRRT

40
(No Transcript)
41
(No Transcript)
42
Hemoperfusion
  • Extracorporeal form of treatment where large
    volumes of blood is passed over an adsorbent
    surface
  • Activated carbon (irreversibly bound by van der
    Waals forces) and resins (not irreversibly
    bound) are the adsorbents most commonly used.
  • Higher MW (100-40,000 daltons) are well adsorbed
    with charcoal having greater affinity for water
    soluble and resin for lipid soluble compounds
  • Time factor

43
(No Transcript)
44
MARS
  • Molecular Adsorbent Recirculating System
  • Effectively removes protein bound toxins

45
(No Transcript)
46
(No Transcript)
47
Diuresis at controlled pH
  • Nonionized drugs are lipid soluble and will
    diffuse through cell membranes relatively easily,
    promoting passive absorption of filtered drugs.
    By contrast, drugs in the ionized states are poor
    absorbed. Alteration in the urine pH can alter
    the absorption of weak acids and bases.

48
Nephrotoxicity
49
Causes of Acute Renal Failure
? GFR
Valeri A, Neusy AJ. Clin Nephrol.
199135(3)110-118. Rao TKS, Friedman EA. Am J
Kidney Dis. 199525(3)390-398. Perazella MA. Am
J Med Sci. 2000319(6)385-391.
50
TENOFOVIR
  • Tenofovir closely related to adefovir
  • Adefovir is a well described nephrotoxin
  • Tenofovir freely filtered also secreted by
    proximal tubule
  • Nephrotoxicity vigilance in clinical trials

Adefovir
Tenofovir
Blood
Lumen
Proximal Tubule
TDF
OAT1
MRP
51
(No Transcript)
52
(No Transcript)
53
(No Transcript)
54
Toxicology
55
(No Transcript)
56
(No Transcript)
57
(No Transcript)
58
(No Transcript)
59
(No Transcript)
60
(No Transcript)
61
(No Transcript)
62
(No Transcript)
63
(No Transcript)
64
(No Transcript)
65
(No Transcript)
66
(No Transcript)
67
(No Transcript)
68
(No Transcript)
69
(No Transcript)
70
(No Transcript)
71
(No Transcript)
72
(No Transcript)
73
(No Transcript)
74
(No Transcript)
75
(No Transcript)
76
(No Transcript)
77
(No Transcript)
78
(No Transcript)
79
(No Transcript)
80
(No Transcript)
81
(No Transcript)
82
(No Transcript)
83
(No Transcript)
84
(No Transcript)
85
(No Transcript)
86
(No Transcript)
87
(No Transcript)
88
(No Transcript)
89
(No Transcript)
Write a Comment
User Comments (0)
About PowerShow.com